Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 25, 2016 08:05 ET | Source: TESARO, Inc.

TESARO Announces Submission of Investigational New Drug Application for Anti-TIM-3 Antibody TSR-022 to the U.S. FDA

WALTHAM, Mass., April 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the submission of an Investigational New Drug (IND)...
April 21, 2016 16:05 ET | Source: TESARO, Inc.

TESARO to Announce First Quarter 2016 Financial Results on May 5, 2016

WALTHAM, Mass., April 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its first quarter 2016 financial results on Thursday, May 5, 2016, after the close of the U.S....
April 06, 2016 07:00 ET | Source: TESARO, Inc.

TESARO Announces Global Prostate Cancer Collaboration and Licensing Agreement With Janssen

Janssen to develop and commercialize niraparib for patients with prostate cancer worldwide, except in JapanTESARO to receive up to $450 million in upfront and milestone payments, plus...
April 04, 2016 08:00 ET | Source: TESARO, Inc.

TESARO Announces Appointment of Dr. Kavita Patel to Board of Directors

WALTHAM, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the appointment of Kavita Patel, M.D., M.S., F.A.C.P....
March 29, 2016 08:05 ET | Source: TESARO, Inc.

TESARO and MD Anderson Cancer Center Announce Immuno-Oncology Collaboration and Exclusive License Agreement

Goal to identify novel small molecule therapeutics against undisclosed immuno-oncology targets Partnership complements TESARO’s existing immuno-oncology pipeline Goal to identify first clinical...
March 29, 2016 08:05 ET | Source: TESARO, Inc.

TESARO Announces Enrollment of First Patient in Phase 1 Clinical Trial of TSR-042

WALTHAM, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced it has dosed the first patient in a Phase 1,...
March 23, 2016 09:00 ET | Source: TESARO, Inc.

TESARO Announces Validation of Marketing Authorisation Application for Oral Rolapitant by the European Medicines Agency

WALTHAM, Mass., March 23, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Marketing Authorisation Application (MAA) for...
March 18, 2016 16:05 ET | Source: TESARO, Inc.

TESARO Announces Closing of $155 Million Private Placement

WALTHAM, Mass., March 18, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, announced today it has completed its previously announced private...
March 14, 2016 08:05 ET | Source: TESARO, Inc.

TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration

WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
February 25, 2016 16:06 ET | Source: TESARO, Inc.

TESARO Announces Fourth-Quarter 2015 Operating Results

U.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial...